<DOC>
	<DOCNO>NCT00861315</DOCNO>
	<brief_summary>Inclusion patient undergoing mechanical ventilation present pneumonia order determine serum pharmacokinetics nebulized amikacin . The primary aim determine dose amikacin nebulized order observe amikacin serum concentration close inferior observed standart intravenous amikacin infusion .</brief_summary>
	<brief_title>Pharmacokinetics Nebulized Amikacin Patients With Pneumonia Undergoing Mechanical Ventilation</brief_title>
	<detailed_description>After inclusion , patient undergo intravenous infusion 20 mg/Kg amikacin amikacin serum concentration monitor follow 24 hour . Randomization occur first amikacin infusion . Patients randomize group nebulized amikacin intravenous amikacin . The three next day study patient recieve nebulized amikacin ( nebulized placebo ) mechanical ventilation placebo infusion ( amikacin infusion case placebo nebulization ) use air drive jet nebulizer . Amikacin serum concentration monitor 24 hour nebulization . Patients follow 10 day safety efficacy . The dose amikacin nebulized 60 mg/Kg first 6 patient ( phase A ) , 80 mg/Kg next 6 patient ( phase B ) 100 mg/Kg last 6 patient ( phase C ) . Each phase start review result preceeding phase idependent safety monitor board .</detailed_description>
	<mesh_term>Pneumonia</mesh_term>
	<mesh_term>Pneumonia , Ventilator-Associated</mesh_term>
	<mesh_term>Amikacin</mesh_term>
	<criteria>Patients admit intensive care unit . Patients undergoing mechanical ventilation 48H . Suspicion ventilator associate pneumonia . Allergy amikacin compound medication . Body mass index &gt; 30 kg/m2 . Myasthenia gravis . Acute chronic renal failure . Vestibulocochlear disease . Pregnancy . Brain death .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>March 2009</verification_date>
	<keyword>Pneumonia</keyword>
	<keyword>Nebulization</keyword>
	<keyword>Amikacin</keyword>
</DOC>